Results 1 to 10 of 25 matches
Category 5 - DIAGNOSTIC IMAGING SERVICES
Category 5 - DIAGNOSTIC IMAGING SERVICES
Category 5 - DIAGNOSTIC IMAGING SERVICES
Related Items: 61647
Category 3 - THERAPEUTIC PROCEDURES
15559 - Additional Information
DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 2 COMPLEXITY where:
(a) dosimetry for a two phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, two planning target volumes and one organ at risk defined in the prescription; or
(b) dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and two organ at risk dose goals or constraints defined in the prescription; or
(c) image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 1 complexity.
All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images
Fee: $866.55 Benefit: 75% = $649.95 85% = $783.15
(See para TN.2.3 of explanatory notes to this Category)
Category 3 - THERAPEUTIC PROCEDURES
15562 - Additional Information
DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 3 COMPLEXITY - where:
(a) dosimetry for a three or more phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, three planning target volumes and one organ at risk defined in the prescription; or
(b) dosimetry for a two phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, and
(i) two planning target volumes; or
(ii) two organ at risk dose goals or constraints defined in the prescription.
or
(c) dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and three organ at risk dose goals or constraints defined in the prescription;
or
(d) image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 2 complexity.
All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images
Fee: $1,120.75 Benefit: 75% = $840.60 85% = $1,037.35
(See para TN.2.3 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61523 - Additional Information
Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61529 - Additional Information
Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61538 - Additional Information
FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)
Fee: $901.00 Benefit: 75% = $675.75 85% = $817.60
Category 5 - DIAGNOSTIC IMAGING SERVICES
61541 - Additional Information
Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $869.60
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61553 - Additional Information
Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R)
Fee: $999.00 Benefit: 75% = $749.25 85% = $915.60
(See para IN.0.19 of explanatory notes to this Category)
Results 1 to 10 of 25 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change